Navigation Links
Oncothyreon to present at BIO Investor Forum 2008
Date:10/24/2008

SEATTLE, Oct. 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the 7th Annual BIO Investor Forum in San Francisco on Friday, October 31, 2008 at 8:00 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentation can be accessed at http://www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
2. Oncothyreon announces prioritization plan for development programs
3. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
4. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
5. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
6. Oncothyreon to receive milestone payment
7. Oncothyreon Reports First Quarter 2008 Financial Results
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
10. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
11. Oncothyreon announces effectiveness of shelf registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Point, IA (PRWEB) , ... January 17, 2017 ... ... from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance System ... to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean herbicide. ...
(Date:1/17/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... earnings conference call will be broadcast live over the ... Eastern Time.  A news release detailing the quarterly and ... Eastern Time the morning of the conference call. ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:1/17/2017)... , Jan. 17, 2017  Only nine percent ... patients over profits, while only 16 percent believe health ... released today. Meanwhile, 36 percent of U.S. adults believe ... patients over profits, compared to hospitals (23%). ... maelstrom," said Wendy Salomon , vice president of ...
(Date:1/17/2017)... Boston, MA (PRWEB) , ... January 17, 2017 ... ... of the completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment ... be validating these new tools and assays, and their applicability in drug safety ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
Breaking Biology News(10 mins):